Spyre Therapeutics
SYRE
71 hedge funds and large institutions have $159M invested in Spyre Therapeutics in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 6 closing their positions.
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
108% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 12
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
29% more capital invested
Capital invested by funds: $123M → $159M (+$36.1M)
18% more funds holding
Funds holding: 60 → 71 (+11)
0% more ownership
Funds ownership: 2.74% → 2.74% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$4.17M |
| 2 |
Goldman Sachs
New York
|
+$3.22M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$3.13M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.13M |
| 5 |
ACM
Aisling Capital Management
New York
|
+$2.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$4.8M |
| 2 |
Man Group
London,
United Kingdom
|
-$286K |
| 3 |
Squarepoint
New York
|
-$173K |
| 4 |
Morgan Stanley
New York
|
-$152K |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$116K |
SYRE Hedge Fund Activity: Q1 2019 in Review
71 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q1 2019, worth a combined $159M — up 29% from $123M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new SYRE positions and 6 closed out — a net gain of 11 holders — while 25 added to existing stakes and 12 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $4.17M. The largest seller was Jennison Associates, cutting an estimated $4.8M.
- 71 institutional investors held Spyre Therapeutics (SYRE) as of Q1 2019, up from 60 in Q4 2018.
- Funds reported $159M of Spyre Therapeutics stock for Q1 2019, up 29% quarter-over-quarter.
- 17 funds opened new Spyre Therapeutics positions in Q1 2019 and 6 closed out, a net change of +11 holders.
- The largest Spyre Therapeutics buyer in Q1 2019 was Deerfield Management, an estimated $4.17M added.
- The largest Spyre Therapeutics seller in Q1 2019 was Jennison Associates, an estimated $4.8M sold.
Based on aggregated 13F filings for Q1 2019.